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Abstract
Candida spp. strains are characterized by their ability to form a biofilm structure on 
biotic and abiotic surfaces, causing significant problems in many industrial branches 
and threatening human health. Candida biofilm is a heterogeneous, spatially well-orga-
nized structure consisting of planktonic and mycelial yeast forms which are interdepen-
dent in the quorum sensing system and surrounded by an extracellular polysaccharide 
substance. Biofilm-forming microorganisms are characterized by high invasiveness, 
the ability to cause dangerous and difficult to treat infections. Furthermore, the cells 
in the biofilm, compared to planktonic forms, show reduced sensitivity to chemical 
compounds with antifungal activity and increased survival under unfavorable envi-
ronmental conditions. The chapter focuses on the emergence of antifungal resistance 
with the development of biofilms. The work presents the examples of antibiotic resis-
tance of a variety of Candida, showing that a group of strains expressing intermediate 
sensitivity or resistance to the tested antibiotics include both clinical and food-borne 
isolates. Similarities in enzymatic and biochemical profiles of different origin isolates 
are discussed. A substantial heterogeneity within Candida albicans group is also under-
lined. Simultaneously, the incidents of biochemical profiles conformity of some clinical 
and food-borne isolates are presented, which may be a result of Candida transmission 
via food.
Keywords: Candida albicans, non-albicans Candida, Candida biofilm, drug resistance,  
food-borne Candida
1. Introduction
Unicellular forms of yeast are rarely found in nature as single, scattered cells, in the form of 
plankton but they are rather adsorpt at the solid-liquid, liquid-gas, or liquid-liquid interface. 
Generally, they form organized, settled structures taking the form of multicellular clusters 
forming biofilm. Biofilm, also called as the biological membrane, is a complex, multicellular, 
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and multifunctional structure of one or more species of microorganisms, surrounded by a 
layer of organic and inorganic substances produced by these microorganisms adhering to 
both biotic and abiotic surfaces. The form of biofilm enhances the effectiveness of microbial 
protection against the adverse environmental factors, including antibiotics, reduces the effec-
tiveness of host defense mechanisms, facilitates the acquisition of nutrients, creates the possi-
bility of horizontal gene transfer by providing evolutionary and genetic diversity, and enables 
the transmission of information between microbial cells [1–3].
Biofilm is most commonly formed on solid surfaces staying in contact with water, living 
tissues, and liquid-air interface. This ubiquitous structure can be very useful but also dan-
gerous being difficult to be removed. Biofilm plays a key role in a process of self-cleaning 
of surface-, ground-, and underground water. The biofilm’s ability to create a biobarrier 
has been exploited in water treatment and to reduce a pollution of soil and ground waters. 
Biofilm also allows biological removal of pollutants from sewage [2]. Biofilm exists not only 
in the natural environment but also is industrially applied, for example, to catalyze complex 
chemical reactions. Natural microbiota of the body of a healthy person forms a biofilm mod-
ulating some physiological functions, for example, colonic biofilm [4]. Moreover, changing 
environmental conditions may transform a biofilm from a big friend into a fierce enemy. A 
good example is the biofilm of the gastrointestinal tract, which, in unfavorable conditions, 
can become a source of mortal danger. In public facilities such as hospitals, hotels, swim-
ming pools, physiotherapeutic facilities, sanatoria, mass caterers, schools and kindergar-
tens, homes, and enterprise of the cosmetic and food industries, biofilm structure allows 
saprophytic and pathogenic microorganisms to survive washing, cleaning, and disinfection 
processes. Biofilm formed in a water supply network poses a sanitary risk to the public. In 
addition, the pipes water network is subjected to microbiological corrosion. Most food pro-
cessing plants are struggling with the problem of biofilm formation in water distribution sys-
tems, refrigeration systems, and heat exchangers. In the food industry, biofilm can colonize 
not only sewage systems, but also machine working surfaces and food products. Biofilm on 
work surfaces, even those made of stainless steel, glass, or Teflon, can lead to food contami-
nation with spoilage microorganisms, including pathogenic ones. Contaminated products of 
both plant and animal origin can cause serious human illnesses as well as huge losses in the 
food industry [2]. Biofilm microorganisms are characterized by increased invasiveness and 
the ability to cause serious infections, even in hospital. Ability to create biofilm is one of the 
pathogenicity factors of the microorganism. Most often, infections caused by biofilm-build-
ing microorganisms are the result of the abiotic surfaces colonization and account about 65% 
of all infections [1]. Microorganisms inhabiting medical materials both biomaterials within 
the human body such as vascular and intraperitoneal catheters, artificial valves, prostheses, 
implants, lenses, stitches, and diagnostic devices such as endoscopes, fibroscopes, and laryn-
goscopes are also an important problem. Biofilm formation on these devices is the cause of 
serious infections and also leads to device damage [1, 2, 5–7]. Microorganisms that inhabit 
the human body also occur mainly in the form of biofilms. These biofilms are mostly com-
posed of symbiotic microorganisms, but also opportunistic ones may occur, which in homeo-
stasis disturbances lead to a development of serious infections. The situation is particularly 
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dangerous, if the development of infection is accompanied by a dysfunction of the device 
colonized by biofilm.
2. Biofilm definition
Biofilm is defined as a well-organized, three-dimensional social structure surrounded by extra-
cellular matrix and irreversibly bound to the surface, built by microorganisms with altered, 
with respect to planktonic form, genotype properties [5, 6, 8–10]. Biofilm enables microorgan-
isms to survive in a changing and unfavorable environment, and therefore is the dominant 
form of their existence in the nature. It is characterized by structural heterogeneity, genetic 
diversity, complexity of interaction, and the presence of extracellular substances. It can be 
either mono- or multilayer, produced by one species or many different species. The biofilm 
structure depends on many factors such as hydrodynamic conditions, surface type, pH of the 
environment, microbial mobility, intercellular communication, nutrient content, exopolysac-
charides, proteins, or oxygen. Colonization of various surfaces by microorganisms is possible 
due to their adhesive properties and extracellular polymeric substances (EPS) stabilizing the 
biofilm structure. Adjacent microorganisms, in a spatially organized structure, produce a com-
mon layer of polymeric substances called extracellular matrix, the complex compounds playing 
an important role in the formation and functioning of the biofilm. Most EPS polysaccharides 
are the organic compounds with long linear or branched molecules of 106 Da. The amount of 
polymers depends on the quantitative and qualitative composition of nutrients. The percentage 
of water in the biofilm matrix is up to 97%. Polymers ability to cyclical accumulation simultane-
ously with donation of water gives the matrix hydrogel features with exceptional viscoelastic 
properties [2, 11–14]. Matrix hydrogel nature effectively protects biofilm microorganisms from 
desiccation and provides the cells with protection against environmental stress factors such as 
UV radiation, temperature shifts, pH fluctuations, or toxic substances [2, 5, 7]. The matrix serves 
also as a communication system between biofilm cells, where chemical and physical signals 
are transmitted through a branched open channel system separating individual microcolonies. 
Thanks to the channel network, oxygen and nutrients are delivered through the channels and 
the excreted waste products are discharged. Cells in biofilms are present in various metabolic 
states. On the periphery of the biofilm, where the channel network system is more developed, 
the cells are large, metabolically active, and its reproducing increases the biofilm thickness. 
While, microorganisms located inside the biofilm are partially cut off from the water system, 
which results in their growth rate decreasing. They may also fall in an anabiosis with possible 
activation in a case of destruction of the outer cell layer, which, no matter how long the biofilm 
works, uses the features of young biofilm cells [2, 12, 13]. The biofilm cell has different char-
acteristics than the planktonic cells. An important determinant of biofilm properties is quorum 
sensing, a specific communication system, strictly controlled by specific genes in response to the 
abundance of cells in the biofilm—the sense of the piston. The ability of cells to communicate 
makes the biofilm able to function in a way that resembles an almost one multicellular organ-
ism consisting of physiologically diverse subpopulations of microbial cells [2, 4, 5, 12, 13, 15].




The process of biofilm formation is multistage and depends on the properties of the micro-
organisms, the construction, and properties of the colonized materials or the host. There are 
four basic phases: (I) reversible adhesion, (II) irreversible adhesion, (III) biofilm maturation, 
and (IV) dispersion (Figure 1).
Biofilm formation begins with the adhesion of free floating microorganisms to the biotic or 
abiotic surface. Reversible adhesion is the result of relatively weak physical interactions caus-
ing the first cells to attach to a solid surface such as gravitational interaction, electromagnetic 
surface charge, van der Waals forces, electrostatic, and hydro- and thermodynamic forces 
(Brownian motion). These forces play a crucial role when the distance between cells and the 
surface is relatively large. Biofilm is unstable and can easily be removed by both chemical 
and physical methods. When the cell distance from the surface is less than 1.5 nm, there is 
irreversible adhesion due to the formation of specific bonds. First microbial cells attached 
to the surface help attaching another one by the formation of hydrophobic, non-specific or 
specific hydrogen bonds, and pairs and ionic complexes (carbon-carbon covalent bonds) [2, 5, 
12, 13]. An important place in the biofilm-building process is the interaction of specific recep-
tors, adhesives, and ligands on the cell surface of the microorganism or the target host cell 
extracellular ligand. Initially, the surfaces are covered by a single layer of microbial cells. In 
the construction of the basic EPS matrix, which gives the biofilm a defined shape and struc-
ture, the increased synthesis and secretion of extracellular biopolymers is important. Biofilms 
expand by increasing the intensity of cell proliferation. While, glycocalyx, a shell composed 
of polysaccharide residues of glycolipids and glycoproteins, the components of the cell mem-
brane, is produced up to the total surroundings of the microcolonies. At this stage, biofilm, in 
addition to living microorganisms, also includes dead cells, mineral substances, and organic 
compounds. These elements are joined by further microbial cells. Irreversible adhesion allows 
the formation of microcolonies and biofilm maturation [5, 12, 13]. Biofilm maturation is fol-
lowed by the microorganisms’ reproduction, their gradual differentiation and the activation or 
inhibition of expression of certain genes. Biofilm cells acquire features that are not expressed 
by planktonic cells and can transmit them to adjacent and progeny cells. When reaching the 
Figure 1. Biofilm formation phases: (I) reversible adhesion, (II) irreversible adhesion, (III) biofilm maturation, and (IV) 
dispersion (elaborated according to [2]).
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 critical thickness of the biofilm membrane, cells migrate from peripheral parts of the mature 
biofilm to the surrounding environment and the process of  colonization begins. Disconnecting 
cells from biofilm and its dispersion is an intentional separation resulting from a reaction to 
adverse environmental conditions. Biofilm adapts to environmental stresses and the detached 
cells begin the process of colonization of new surfaces [2, 3, 5, 8, 12, 13].
Both bacterial and fungal biofilms, in medicine and in industry, were first described in 1978 [7]. 
Since then, it has been the subject of numerous studies that aim to understand the molecular 
mechanisms of its origins and the role it plays in infections and drug resistance [5]. Candida albi-
cans often occurs in the form of biofilm, which is the etiological factor of approximately 90% can-
didiasis. Among the clinical strains of the genus Candida, biofilm formation depends on the type 
of a strain [16], and Candida albicans, even of the same genotype, may differ in biofilm features [1].
4. Candida dimorphism and the biofilm formation
Compared to planktonic forms, biofilm cells lead settled lifestyles and have characteristic gene 
expression associated with the growth rate and synthesis of some of the adhesion and enzyme 
proteins. Fungal biofilms with cells differing phenotypically and functionally usually are of 
much more complex structure than the bacterial biofilm. Polymorphism is a characteristic fea-
ture of Candida yeast. The planktonic Candida are usually in a form of blastospores (budding 
cells), while the biofilm structure is formed by both blastospores and mycelial forms. During 
biofilm formation, morphological transformation takes place: from blastospores through the 
germ tubes to the filamentous forms (mycelium or pseudomycelium). The plasticity of Candida 
biofilm indicates that its cell composition may also change depending on the location and 
characteristics of the biomaterial surface. Individual cell types exhibit differences in antigenic 
structure and its adhesion and invasive properties, enzymatic activity, and phagocytosis resis-
tance. Blastospores are responsible for the adhesion and spreading of the biofilm, initiating its 
production by adhering to biotic and abiotic surfaces and its colonization [5]. Adhesion is a 
signal that induces germination (morphogenesis) of blastospores and the formation of invasive 
forms, mycelium, or pseudomycelium, that enter epithelial or endothelial cells via endocytosis 
or active penetration and because of enzymatic activity they contribute to the destruction of 
colonized tissues. The presence of mycelial forms is not a prerequisite condition for the biofilm 
formation; however, it seems indispensable in the process of maturation. In the mature Candida 
biofilm, the inner layer is composed of blastospores, and the outer multilayer is mycelium and 
pseudomycelium. Biofilms created by Candida sp. yeast can reach a thickness of 25–450 μm 
[1, 5, 10, 11, 17]. There are three [6, 11] or four [1, 18] phases of Candida biofilm formation. 
Sometimes the last dispersion phase is included in the third phase, maturation of the biofilm.
5. Candida adhesion and the ability to the biofilm formation
The biofilm structure depends on the specific gene expression resulting from yeast contact with 
biotic or abiotic surface. Candida albicans yeast contact with a specific surface and activate the 
mitogen-activated protein kinase (MAPK) signaling cascade, which carries the extracellular 
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contact signal to eukaryotic cells, then activating transcription factors and expressing a specific 
set of genes responsible for adherence. MAPK gene mkc1 activity level is higher in cells growing 
on different surfaces than in planktonic cells. After contacting Candida albicans with a polysty-
rene surface, the transcriptional level of the gene coding for methionine and cysteine, and the 
cdr1 and mdr1 codes for the mechanism of active ejection of the drug by efflux are surprisingly 
increased. Some examples of Candida sp. adhesion to polystyrene are presented in Figure 2.
Genes encoding sulfur amino acids are responsible for the amount of biofilm biomass pro-
duced, while the expression of the cdr1 and mdr1 genes is associated with the acquisition of 
drug resistance by the biofilm phenotype. What is more, the activity of adh1 alcohol dehydro-
genase is higher in plankton cells than in biofilm cells, which influences the biofilm formation 
[1]. This enzyme is probably responsible for inhibition of biofilm formation and inactiva-
tion or mutation of the adh1 gene results in stronger biofilm formation in vitro and in vivo 
[1, 5]. Adhesion to both biotic and abiotic surfaces related to recognition of host cell surface 
receptors, is a precondition for colonization, biofilm formation, initiation, and development 
of infection. Lack of adhesion prevents yeast cells from biofilm formation. Phenotypic vari-
ability and plasticity of cells in relation to changing environmental conditions allow for the 
settlement of new surfaces. Numerous Candida albicans gene products important for biofilm 
development have been identified [1, 19]. Adhesive genes can be activated by different envi-
ronmental signals. The potential adhesives involved in biofilm formation are cell wall surface 
proteins. The input of surface proteins with GPI (glycosylphosphatidylinositol) module is 
decisive in the formation of fungal biofilm. Ability of Candida albicans to adhesion is an impor-
tant virulence factor associated with glycoproteins encoded primarily by genes such as hwp1 
and als. Such an effect leads to changes in the expression of genes encoding cell wall proteins 
glycosylphosphatidylinositol dependent. Several key adhesins: als1, als2, als3, als4, als5, eap1, 
hwp1, hydrolases, lipases, phospholipases, and transcriptional factors bcr1 regulating protein 
expression are responsible for biofilm formation [1, 5, 19, 20]. Ywp1, mannoprotein with a GPI 
Figure 2. Adhesion to a polystyrene surface of environmental Candida sp. strains (a) Candida albicans cl/MP/12 clinical 
isolate; (b) Candida parapsilosis Fo/82/03 food-borne isolate; (c) Candida albicans cl/MP/08 clinical isolate (photographs by 
M. Maroszyńska).
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module, is both the regulator of adhesion and a marker of Candida albicans cells. Blastospores 
are characterized by weaker intercellular adherence than mycelial forms. In addition, they are 
probably equipped with mechanisms to regulate the activity of their own adhesins [1]. The 
ywp1 protein found on yeast cells, a known adherence regulator, can function as an antihis-
tamine and inhibit adherence. The discovery of the ywp1 protein is a scientific proof for the 
presence of the cell diffusion phase in the biofilm’s life cycle. The deletion of the ywp1 gene 
leads to the enhancement of the blastospor adherence to the various surfaces [1]. On the other 
hand, in the biofilm layer composed of pseudomycelium Candida albicans identified adhesins 
with GPI, HWP1, EAP1 module, and the ALS adhesin family. Some studies indicate that the 
genes als and eap1 within the Candida genus show similarity to the genes regulating adhesion 
in Saccharomyces cerevisiae [1]. While, the hwp1 gene, known as the gene coding for the main 
Candida albicans protein, is involved in many functions such as cell wall building, intracellular 
signaling, and the development of hyphae. In addition, it appears that it is involved in the 
adhesion of yeast to epithelial cells, which is so important in the initial colonization stage. 
There is also an evidence for the involvement of the hwp1 gene in systemic candidiasis patho-
genesis on mouse model in vivo. It has been shown that strains having the hwp1 and hwp1-null 
heterologous genes showed, respectively, reduced and no virulence compared to control wild 
strains. Hwp1 is the first exposed adhesive, required for biofilm formation in vivo, which is 
not present on cells in the form of yeast and plays no role in the formation of microcolonies. 
However, it expresses during morphogenesis blastospores to pseudomycelium [1].
6. Candida germ tubes and the ability to the biofilm formation
Pseudomycelium is formed by a germ tube process and as a key component of the biofilm pro-
vides its integrity. Both morphological forms of blastospore and pseudomycelium are capable 
of a biofilm formation, but strains capable of growth only in the form of blastospores produce 
only residual biofilm. The transcription factor efg1 plays a key role in regulating the morphol-
ogy and virulence of yeast Candida albicans. It was first identified as an inducer of the develop-
ment of pseudomycelium in Saccharomyces cerevisiae and then as a necessary for the growth 
of mycelium Candida albicans. The consequence of deletion of this gene is a loss of ability to 
transition into mycelial forms in response to majority of stimulation factors, but may occur 
in hypoxia and abiotic conditions. The efg1 gene fulfills many of the important functions in 
Candida albicans yeast cells, and most important is the virulence of vast infection models. Cells 
with efg1 gene deletion do not attack the human epithelium. In addition, efg1 is one of the key 
regulators of transition from the “white” form to the “opaque” form and essential to keep the 
default “white” phenotype. Moreover, unlike many other biofilm process regulators, the efg1 
gene is essential for biofilm development under hypoxia and oxygenation conditions. Even 
when the yeast cells have adhered to the abiotic surface it is necessary to produce resistance 
to antifungal agents. Efg1 is a part of a network of six transcription factors that regulate the 
expression of at least 1000 genes involved in the development of the Candida albicans biofilm 
[21]. Several thousands of intergenic regions bound by the transcriptional factor efg1, which 
binds to promotors at least 53 genes in Candida albicans, including many transcription factors 
have been identified. The binding of efg1 is closely related to the transition from the basic 
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form of the yeast cell to the pseudomycelium. Mutants with the deletion of efg1, cph1, and tec1 
genes encoding transcription factors do not form pseudomycelium, and consequently have 
no ability to form mature biofilm structures. This indicates that transcriptional factors efg1, 
cph1, and tec1 play a key regulatory role in the formation of mature Candida albicans biofilm 
[1, 21]. Furthermore, the mutations of the genes suv3, nup85, mds3, and kem1 inhibit the for-
mation of pseudomycelium, which in turn promotes the formation of “immature” biofilm. 
In addition, mutants with the deletion of the bcr1 gene produce pseudomycelium, but do not 
produce biofilm, since the inhibition of gene expression for adhesin als and hwp1, involved in 
biofilm formation and regulated by bcr1 [1]. Separation of the filamentation process and bio-
film formation showed that the morphogenesis of blastopores to pseudomycelium and con-
sequently the presence of pseudomycelium did not clearly determine the biofilm formation. 
Pseudomycelium is only a basis, on which under control of the transcription factor bcr1, the 
adhesins gene gradually express. It is therefore necessary to provide the proper function—
filamentous adherence, without which mature biofilm will not be formed. Mutants lacking 
the activity of tec1, bcr1, als3, or hwp1 proteins exhibit large abnormalities in the biofilm 
production, which may underline the importance of all these proteins in the early stages of 
biofilm formation. The ability of residual biofilm formation by these mutants may at the same 
time indicate that these proteins are not directly involved in adherence to the surface, but in 
adherence between the blastospore, the mycelium forms, or the adherence mixed between 
both forms [1, 5, 21].
7. Candida communication and the ability to the biofilm formation
For the proper functioning of biofilm, communication between the cells and density regula-
tion is necessary. These tasks are executed by small signaling particles called autoinducers and 
by responding to the generated signals within population in the quorum sensing system. In the 
culture with a high population density, there are signaling particles which, through diffusion, 
penetrate other cells running different signals. Exchanging signals lead to specific cell effects 
and coordination of cellular activity like multicellular behavior. Candida yeasts produce sev-
eral signaling molecules, the accumulation of which determines the development, existence, 
and breakdown of the biofilm through having a direct influence on the process of mycelial 
forms creation. The best-known molecule is farnesol (C15H26O), a terpene alcohol isolated from 
Candida albicans cells. In the reproduction and maturation phase of the biofilm, the density 
of cells is relatively small, allowing the formation of mycelium. With the cell concentration 
increase, the concentration of farnesol, which interacts with the blastospore cell receptors, is 
increasing, preventing transformation into pseudomycelium and maturation of biofilm. The 
consequence is the phase of the biofilm dispersion in which individual blastospores and their 
aggregates are detached [1, 2, 5, 18]. The release of blastospore requires weakening of the 
adhesive properties, which corresponds to the anti-adhesion ywp1 protein, and the main reg-
ulator of the process is the hsp90 protein [5]. Farnesol exogenously inhibits biofilm formation 
by blocking the expression of many genes responsible for the formation of pseudomycelium 
and induces expression of the adh gene taking part in inhibition of the biofilm formation. The 
endogenous accumulation of this signaling molecule in biofilm structures may therefore be 
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a factor initiating the breakdown of the biofilm upon reaching a critical cell concentration. 
Farnesol also influences the expression of ergosterol metabolism genes. At the time of action of 
azoles blocking the ergosterol synthesis, the substrate to produce this molecule is increased by 
Candida albicans, and the amount of farnesol may even rise 45 times. Farnesol also affects many 
other processes, such as production of chlamydospores, iron transport, and activation of genes 
responsible for antibiotic resistance and oxidative stress. Unfortunately, it also has an adverse 
effect on host cells by inhibiting macrophage activity in the mouse model [1, 2, 5].
Another Candida albicans signaling molecule is an autoinducer thiamazole that stimulates 
the production of mycelium during the intermediate phase of biofilm growth. Comparing 
to planktonic cells, biofilm cells produce higher amounts of thiamazole [2, 18]. It protects the 
cells from a decrease in the expression of DNA replication genes, chromosome segregation, 
and a cell cycle control [1, 2].
The active regulation of the process of detachment from biofilm surface layers, in the state 
of achieving critical concentration of cells inside, is a crucial role of signaling molecules [1].
8. Candida antibiotic resistance
Candida albicans, like most pathogens, developed a number of mechanisms that regulate their 
virulence. It has developed different strategies to colonize host tissues and break down and 
weaken its barriers and defense mechanisms. One of the most important virulence factors of 
Candida sp. is the ability to produce mycelial forms that allow a host tissue invasion, at the 
same time repelling an effective phagocytes attack. The virulence of Candida sp. is strongly 
related to proteins determining of cell integrity, adherence, colonization, or change of phe-
notypic forms. These proteins are also an effective weapon in the fight against host defense. 
Most of them are characterized by the presence of anchored glycosylphosphatidylinositol and 
represent 88% of all covalently bound Candida albicans cell membrane proteins. Increasing 
clinical drug resistance because of abuse of antimicrobial agents is an important phenomenon 
hindering the fight against these yeasts. Candida albicans drug resistance is closely related to 
the antifungal activity of the drugs used.
Most drug resistance mechanisms to antifungal agents are the results of gene mutations. 
Usually, these are point mutations of genes encoding drug-binding molecules, enzymes of 
metabolic pathways, or transcription factors [22]. Such mutations are stable and their acquisi-
tion takes time. It is believed that they are the expression of a cell response to chronic stress, 
for example, resistance-inducing azoles [23] or genetic aneuploidy [24], which changes the 
expression of multi-drug pump points or transcription factors. Antifungal drugs can also acti-
vate a classic, immediate response to a stress. Resistance acquired on this path does not involve 
the change of genetic material and is reversible, for example, Candida sp. phenotype form 
change or biofilm formation. This reversible change allows us to obtain the time necessary to 
induce permanent resistance dependent on genetic mechanisms. For the resistance of one of 
the oldest antifungal agents, 5-FC, the most responsible is uracil phosphoribosyltransferase 
mutation preventing conversion of 5-fluorouracil to fluorouradine 5- monophosphate [25]. 
Candida Biofilms: Environmental and Clinical Aspects
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Resistance to polyene, which is still relatively rare today, is obtained by decreasing ergosterol 
content in the cell membrane, inter alia by erg3 gene mutation. Lowering ergosterol content 
in the cell membrane also leads to azole resistance by the increased expression of the erg11p 
molecule, the azoles binding point. Point mutations of this molecule are responsible for 
replacing the toxic ergosterol precursors accumulated in the yeast cell by non-toxic ones [25]. 
In vitro studies show different patterns of drug resistance to azoles, frequently overlapping 
with clinical trials. In vitro, the role of the hsp90 molecule chaperone for calcineurin in pro-
moting the rapid acquisition of Candida albicans resistance to fluconazole has been identified 
[26, 27]. Interestingly, the ability to maintain azole resistance even after treatment has ended 
[28]. Another effective mechanism of azoles resistance is the high expression of multilayer 
membrane pumps (MFS Mdr1p drug pump or ATP binding cartridge (ABC) of the Cdr1p or 
Cdr2p pump). These pumps beside azoles are active against a variety of other drugs, apart 
from echinocandins [25, 29]. Limited resistance to echinocandin is most likely related to their 
relatively rare use. Although, in recent years, there have been reports both in vitro and in vivo 
on Candida sp. resistance to echinocandins. The best-known mechanism of resistance to these 
antibiotic agents is the mutation of the β-1,3-d-glucan synthase Gsc1p subunit [25, 29].
9. Candida biofilm and its drug resistance
Particularly dangerous from a clinical point of view is the ability of most clinically important 
Candida species (Candida albicans, Candida dubliniensis, Candida glabrata, Candida krusei, Candida 
tropicalis, and Candida parapsilosis) to biofilm formation. The clinical significance of biofilm is 
increasing with the increasing introduction of various medical devices into the human body. 
Almost all the contaminations of these devices are the results of their colonization by micro-
organisms forming organized biofilm structures.
Biofilm Candida sp. is characterized by high resistance to all antifungal agents currently used: 
azoles (fluconazole, itraconazole, voriconazole, posaconazole), echinocandins (kaspofungin, 
mikafungin, anidulafungin), amphotericin B, flucytosine, but the level of this resistance is 
different for different drugs. Studies have shown that Candida sp. biofilm is resistant to flu-
conazole at a concentration of 2000 times higher than the MIC value for the planktonic form. 
The liposomal form of amphotericin B and echinocandin are the most active against Candida 
sp. biofilm. These antibiotic agents exhibit anti-biofilm activity in concentrations 2–25 times 
higher than the MIC values against planktonic forms [25, 30, 31]. Biofilm resistance is a com-
plex, multi-factor phenomenon that uses the different mechanisms generated by planktonic 
forms at different stages of biofilm formation. There is also the possibility of generating dif-
ferent mechanisms of drug resistance by individual cell in the biofilm. For example, in the 
early stages of biofilm-building with low cell concentration, the increase in the activity of 
drug pumps, lowering the intracellular concentration of azoles, is noted. In mature biofilms 
characterized by greater cell concentration and many extracellular substances, resistance to 
amphotericin, azoles, and echinocandins is generated [11, 25, 30]. In addition, it appears that 
the lower content of ergosterol in mature biofilm is also one of the mechanisms of defense 
against antifungal agents [22]. The change from planktonic forms to biofilm is a response to 
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unfavorable environmental conditions, which starts a rapid response to stress, which gener-
ates, for example, drug resistance. Acquired by acute stress resistance, it is associated with 
protein kinase activity, calcineurin or hsp90p heat shock protein. Drug-resistant subpopula-
tion protects the pool of cells needed to rebuild the biofilm [25]. An extracellular matrix (ECM) 
is an important factor in the generation of multi-drug resistance. β-1,3-d-glucan, one of the 
ECM components, is responsible for drug resistance to fluconazole and amphotericin B. While 
the role of ECM in generating multi-drug resistance is unquestioned, the mechanisms leading 
to it remain unexplained.
In the fight against Candida biofilm, there are two main problems: a penetration of the drug 
into the biofilm structure and to overcome the yeast resistance produced by the cells orga-
nized in the biofilm. A method of “lock therapy” is conformed to deliver the antifungals 
directly into the places colonized by the biofilm. To conquer the growing antibiotic biofilm 
resistance the following strategies are applied: (i) novel antifungal agents in the forms of con-
jugates, (ii) a multi-drug therapy, (iii) a combination of antifungal agents with nonsteroidal 
anti-inflammatory drugs, and (iv) agents interfering the communication of cells in the biofilm.
The use of high drug concentrations, for example, higher echinocandin doses used to treat 
endocarditis, is one of the proposed methods of fighting against Candida sp. biofilm. “Lock 
therapy” uses medical devices (e.g., vascular catheters) for treatment, where high drug doses 
are introduced into the catheter [32, 33].
Hudson et al. [34] describe a novel form of amphotericin B, dextran aldehyde conjugate with 
amphotericin B, preservative gel formulation used in local treatment of infections (ligaments, 
vascular catheters, bones) caused by Candida sp. biofilm. In vitro, also other compounds: 
EDTA, ethanol, and high doses of monocycline, are effective in the fight against Candida sp. 
biofilm as “lock therapy” [32, 35].
Another method of fighting infections caused by Candida sp. biofilm is the combination ther-
apy of antifungal agents (fluconazole, echinocandin, and amphotericin B) with calcineurin 
inhibitors such as cyclosporin A or tacrolimus. Such therapy exhibited good in vivo activity 
in the treatment of rat-associated venous catheter infections [35]. Other promising prepara-
tions used in “lock therapy” in combination with antifungal agents are compounds that target 
hsp90 heat shock proteins such as geldanamycin [25, 35]. However, none of these prepara-
tions are suitable for systemic use due to their toxicity or lack of confirmed safety in clinical 
trials.
An interesting proposal seems to be the combination of antifungal preparations with widely 
used nonsteroidal anti-inflammatory drugs (NSAIDs). Their activity by inhibiting cyclooxy-
genase prevents yeasts filamentation and thus biofilm formation [32].
Recently, the synergistic effects of 2-adamantanamine, a structural analogue of antiviral 
amantadine, with fluconazole have been discovered. The mechanism of action is unknown, 
but it appears that 2-adamantanamine inhibits lanosterol 14-α-demethylase in the ergosterol 
cycle [32]. The patients’ safety of such association has not been established.
Attempts are also being made to use molecules responsible for biofilm communication. One of 
them is farnesol, which, more than in physiological concentration, leads to biofilm degradation. 
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Its activity in mouse model studies in vitro was comparable to that of azoles. However, in vivo 
studies on animal models have not been conducted [32, 36].
Pulmozyme preparation, comprising recombinant human deoxy ribonuclease (rkDNase), is 
currently used in inhalation therapy of patients with cystic fibrosis, which targets bacterial 
biofilm DNA [32].
10. Probable environmental circulation of Candida strains
Besides the most frequent fungal pathogen Candida albicans, non-albicans Candida strains are 
isolated from the patients and clinical environments. Among non-albicans, the common clini-
cal isolates are Candida glabrata, Candida lusitaniae, Candida parapsilosis, Candida auris, Candida 
tropicalis, and Candida dubliniensis. Candida sp. are the widespread yeasts in food products 
serving as natural flora members or food-contaminants. The examples of food-associated 
Candida yeasts are Candida lusitaniae, Candida famata, Candida parapsilosis, Candida colliculosa, 
Candida tropicalis, Candida krusei, Candida boidinii, and Candida pelliculosa. Considering the 
possibilities of Candida strains’ natural circulation between food and clinical environments, 
a question arises if the food-borne strains can be a threat for specific groups of patients. Our 
previous work presented the examples of antibiotic resistance of a variety of Candida clini-
cal and food-borne isolates [37]. Within the study, 24 clinical strains of Candida albicans and 
1 Candida glabrata strain as well as a Candida lusitaniae strain were compared with 18 non-
albicans food-borne candidas. The set of food-borne isolates consisted of Candida lusitaniae 
(four strains), Candida famata (two strains), Candida parapsilosis (one strain), Candida colliculosa 
(one strain), Candida tropicalis (one strain), Candida krusei (four strains), Candida boidinii (three 
strains), Candida rugosa (one strain), and Candida pelliculosa (one strain). The strains sensitiv-
ity to the nystatin (polyenes), fluconazole (triazoles I generation), voriconazole (triazoles II 
generation), and caspofungin (echinocandins) were checked. It was found that all the tested 
strains were sensitive to caspofungin but 15 strains differed in sensitivity to nystatin, fluco-
nazole, and voriconazole irrespective of their origin. Interestingly, two of four tested food-
borne strains of Candida krusei were not susceptible to fluconazole, and the third one was 
classified as intermediate. All Candida krusei isolates were sensitive to fluconazole. One clini-
cal isolate of Candida glabrata was not sensitive to fluconazole. Triazoles were the last effec-
tive not totally inhibiting the growth of the clinical isolates and five food-borne strains. The 
results proved that a group of strains expressing intermediate sensitivity or resistance to the 
tested antibiotics include both clinical and food-borne isolates.
According to the biochemical profiles, the tested strains were classified in two groups: (i) 24 
Candida albicans clinical isolates and 1 strain of food-borne yeast Candida tropicalis, which was 
isolated from pickled cucumbers; (ii) 17 food-borne strains and 2 clinical isolates Candida gla-
brata and Candida lusitaniae. What is more, Candida albicans isolates expressed vast biochemical 
heterogeneity. A yeast adaptation to the host organism may explain these differences.
Both Candida albicans and Candida glabrata, typical human pathogens, were not found in food 
[37]. The noted biochemical profiles conformity of some clinical and food-borne isolates may 
be a result of Candida transmission via food. The similarity of food-borne Candida tropicalis to 
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the Candida albicans strains isolated from clinical patients implies the possibility of circulating 
of antibiotic-resistant strains outside the hospital environment and the possible yeast infec-
tion caused by yeasts entered into the body with food.
The plasticity of Candida yeasts subjected to non-conventional antifungal compounds like 
essential oils were also proved [38, 39]. Both Candida albicans and food-borne isolates, Candida 
rugosa, Candida famata, and Candida krusei, have changed their properties at the presence of 
tea tree oil (Melaleuca alternifolia Maiden & Betche Cheel), thyme oil (Thymus vulgaris l.), and 
clove oil (Syzygium aromaticum l. Merr. & L.M. Perry).
11. Conclusions
Biofilm-forming microorganisms, including Candida species, are characterized by high 
invasiveness, the ability to cause dangerous, and difficult to treat infections. Furthermore, 
the cells in the biofilm, compared to planktonic forms, show reduced sensitivity to chemi-
cal compounds with antifungal activity and increased survival under unfavorable envi-
ronmental conditions. The morphological diversity of the biofilm structures formed by 
Candida albicans and non-albicans strains allows these yeasts to colonize both biotic and 
abiotic surfaces. The emergence of antifungal resistance with the development of biofilms 
is still a problem. The incidences of medical equipment colonization by Candida yeasts are 
constantly noted. Moreover, the proven biochemical profiles conformity of some clinical 
and food-borne isolates may be a result of Candida transmission via food.
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